Volume 136, Issue 6 e202316858
Forschungsartikel

Catechol-Isolated Atomically Dispersed Nanocatalysts for Self-Motivated Cocatalytic Tumor Therapy

Dr. Yuemei Wang

Dr. Yuemei Wang

Research Unit of Nanocatalytic Medicine in Specific Therapy for Serious Disease, Shanghai Institute of Ceramics, Chinese Academy of Medical Sciences (2021RU012), Shanghai, 200050 P. R. China

Centre of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing, 100049 P. R. China

Shanghai Tenth People's Hospital, Shanghai Frontiers Science Center of Nanocatalytic Medicine, The Institute for Biomedical Engineering & Nano Science, School of Medicine, Tongji University, Shanghai, 200072 P. R. China

These authors contributed equally to this work.

Search for more papers by this author
Shuwen Qiu

Shuwen Qiu

Shanghai Tenth People's Hospital, Shanghai Frontiers Science Center of Nanocatalytic Medicine, The Institute for Biomedical Engineering & Nano Science, School of Medicine, Tongji University, Shanghai, 200072 P. R. China

These authors contributed equally to this work.

Search for more papers by this author
Dr. Liping Wang

Dr. Liping Wang

Research Unit of Nanocatalytic Medicine in Specific Therapy for Serious Disease, Shanghai Institute of Ceramics, Chinese Academy of Medical Sciences (2021RU012), Shanghai, 200050 P. R. China

Centre of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing, 100049 P. R. China

Search for more papers by this author
Dr. Penghao Ji

Dr. Penghao Ji

Shanghai Tenth People's Hospital, Shanghai Frontiers Science Center of Nanocatalytic Medicine, The Institute for Biomedical Engineering & Nano Science, School of Medicine, Tongji University, Shanghai, 200072 P. R. China

Search for more papers by this author
Dr. Yuedong Guo

Dr. Yuedong Guo

Shanghai Tenth People's Hospital, Shanghai Frontiers Science Center of Nanocatalytic Medicine, The Institute for Biomedical Engineering & Nano Science, School of Medicine, Tongji University, Shanghai, 200072 P. R. China

Search for more papers by this author
Heliang Yao

Heliang Yao

Research Unit of Nanocatalytic Medicine in Specific Therapy for Serious Disease, Shanghai Institute of Ceramics, Chinese Academy of Medical Sciences (2021RU012), Shanghai, 200050 P. R. China

Search for more papers by this author
Chenyang Wei

Chenyang Wei

Research Unit of Nanocatalytic Medicine in Specific Therapy for Serious Disease, Shanghai Institute of Ceramics, Chinese Academy of Medical Sciences (2021RU012), Shanghai, 200050 P. R. China

Search for more papers by this author
Prof. Minfeng Huo

Corresponding Author

Prof. Minfeng Huo

Shanghai Tenth People's Hospital, Shanghai Frontiers Science Center of Nanocatalytic Medicine, The Institute for Biomedical Engineering & Nano Science, School of Medicine, Tongji University, Shanghai, 200072 P. R. China

Search for more papers by this author
Prof. Jianlin Shi

Prof. Jianlin Shi

Research Unit of Nanocatalytic Medicine in Specific Therapy for Serious Disease, Shanghai Institute of Ceramics, Chinese Academy of Medical Sciences (2021RU012), Shanghai, 200050 P. R. China

Centre of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing, 100049 P. R. China

Shanghai Tenth People's Hospital, Shanghai Frontiers Science Center of Nanocatalytic Medicine, The Institute for Biomedical Engineering & Nano Science, School of Medicine, Tongji University, Shanghai, 200072 P. R. China

Search for more papers by this author
First published: 14 December 2023

Abstract

Nanocatalytic tumor therapy based on Fenton nanocatalysts has attracted considerable attention because of its therapeutic specificity, enhanced outcomes, and high biocompatibility. Nevertheless, the rate-determining step in Fenton chemistry, which involves the transition of a high-valence metallic center (FeIII) to a Fenton-active low-valence metallic center (FeII), has hindered advances in nanocatalyst-based therapeutics. In this study, we constructed mesoporous single iron atomic nanocatalysts (mSAFe NCs) by employing catechols from dopamine to coordinate and isolate single iron atoms. The catechols also serve as reductive ligands, generating a field-effect-based cocatalytic system that instantly reduces FeIII species to FeII species within the mSAFe NCs. This self-motivated cocatalytic strategy enabled by mSAFe NCs accelerates the kinetics of the Fenton catalytic reaction, resulting in remarkable performance for nanocatalytic tumor therapy both in vitro and in vivo.

Conflict of interest

The authors declare no conflict of interest.

Data Availability Statement

The data that support the findings of this study are available in the supplementary material of this article.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.